Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab in NOMID / CINCA Syndrome (24‑month open‑label study)
2008-001429-32Phase 3
- Sponsor
- Novartis
- Start
- Mar 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of canakinumab in multisystem inflammatory syndrome (MIS) and cryopyrin-associated periodic syndrome (CAPS), sponsored by Novartis. Primary endpoints: Inflammatory remission (central nervous system) and Inflammatory remission (peripheral blood).
02
Drugs
canakinumab
03
Conditions
multisystem inflammatory syndrome (MIS)cryopyrin-associated periodic syndrome (CAPS)
Beyond the preview
Go deeper on 2008-001429-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001429-32.